FDA
-
-
-
-
-
-
-
Guardant Health (GH) PT Raised to $160 at BTIG, Second Day in a Row
-
-
-
-
-
-
-
Guardant Health gets FDA approval for breast cancer diagnostic test
-
-
-
-
-
-
-
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare
-
-
-
-
-
-
-
Guardant Health posts 39% revenue growth in fourth quarter
-
-
-
-
-
-
-
FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
-
-
-
-
-
-
-
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
-
-
-
-
-
-
-
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

